Investigational amylin receptor agonist

Eloralintide

Eloralintide's terminal half-life in a Phase 1 single-dose trial was 310 to 366 hours (12.9 to 15.3 days); the app lists 336 hours.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Eloralintide after one dose: 50% at ~14 days, 25% at 28 days, 12.5% at 42 days.

Drawn from the half-life in the app's model, ~14 days. The model's figures

Eloralintide (LY3841136) is a selective amylin receptor agonist under development as a once-weekly subcutaneous injection for obesity.2 Eli Lilly is the developer: it funded the 48-week Phase 2 trial that Billings and colleagues reported in the Lancet in 2025.3 The app files it under amylin analogs and grades the evidence as emerging. No prescribing label or approved dose was identified: a DailyMed search for "eloralintide" returned no labels, and the registry entry for the Phase 3 study ENLIGHTEN-2 lists it as recruiting.4

In the Phase 2 trial of 263 adults, mean weight change at 48 weeks (efficacy estimand) ranged from -9% on 1 mg to -20% on 9 mg and on a 6-9 mg escalation, against -0.4% on placebo.3 Nausea and fatigue were the most common adverse events, and their rates differed by regimen: fatigue was 43% on 9 mg and 46% on 6-9 mg against 12% on placebo.3 In an earlier 12-week Phase 1 trial, four participants had mood-related events (one at 6 mg and three at 12 mg), and all three at 12 mg were discontinued from treatment.2

2

How it works

Lilly's Phase 1 authors describe eloralintide as "a selective amylin receptor agonist, exhibiting greater potency at amylin receptors than at calcitonin receptors".2 In cell-line assays reported by Briere and colleagues (Molecular Metabolism, 2025), eloralintide showed "8- to 12-fold more activity for human AMY1R than AMYR3 and CTR".1 These were laboratory results; the same paper lists as a limitation "eloralintide's selectivity for both AMY1R and AMY3R in rats vs only AMY1R in humans".1 The paper also states that "there is no established minimum selectivity threshold to define biologically relevant selectivity".1 It describes cagrilintide as "a non-selective amylin receptor agonist, activating AMY1R, AMY3R, and CTR with comparable relative potency, in both human and rat assays".1 In lean rats, eloralintide "induced significantly less conditioned taste avoidance" than cagrilintide; this is an animal result.1 The Phase 1 multiple-dose authors put forward two explanations for the low gastrointestinal event rate they saw: receptor selectivity, and slow absorption with a long half-life giving relatively flat concentrations.2 The authors call the selectivity explanation a hypothesis, describe the comparison with other amylin receptor agonists as based on indirect data, and write that results from clinical studies with other amylin molecules "will be key to a deeper understanding of the role of selectivity and/or pharmacokinetics on the tolerability and efficacy of amylin agonists".2

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~14 days
Bioavailability
80%
Typical dose
1–9 mg/week
Route
SubQ
Time to peak
~24 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~14 days (336 h)Terminal geometric mean half-life of 310 to 366 h (12.9 to 15.3 days) after single doses of 0.4 to 12 mg in healthy participants; the Phase 1 multiple-dose paper gives "~14‐day half‐life"1,2
Time to peak~24 hMedian time to maximum concentration of 72.0 to 132.2 h across single doses of 0.04 to 12 mg1
Bioavailability80%No published figure identified; the app's value is modelled; the registered Phase 1 study NCT06916065 lists relative bioavailability among its aims5
Dose proportionalityNot an app fieldMultiple-dose trial, 1.2 to 12 mg: AUC and Cmax "approximately dose proportional"; single-dose trial: AUC(0-∞) dose proportional between 0.4 and 12 mg, Cmax "less than proportionally"2,1
Peak-to-trough ratio at steady stateNot an app field1.28 to 1.38, attributed by the authors to slow absorption and the ~14-day half-life2

The app's time to peak (about 24 hours) is shorter than the median 72 to 132 hours reported after single doses, so the page gives both figures.1 Briere and colleagues contrast this with cagrilintide, which they cite as having a half-life of 159 to 195 h and a median tmax of 24 to 72 h at 0.16 to 4.5 mg.1 In the single-dose trial the half-life could not be calculated reliably at 0.04 and 0.12 mg, because it was determined over less than 2 half-lives.1 The trials' pharmacokinetic estimates came from noncompartmental analysis; the app's one-compartment model is its own modelling choice.2

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: once weekly in the Phase 2 trial3.

An illustration from a pharmacokinetic model using a half-life of 336 hours (14 days). It is not a measured level or a suggested dose.

4

Human studies

The table lists the three published trials in people that were identified in PubMed and ClinicalTrials.gov searches on 16 November 2026; all were sponsored by Eli Lilly.

Table 4.1Human studies3 rows
Study and yearDesignPeopleDose and lengthMain result
Briere and colleagues, Molecular Metabolism, 2025 (Phase 1, single dose)1Randomised, placebo-controlled, participant/investigator-blinded; all authors Lilly employees and shareholders48 healthy participants, mean BMI 27.5 kg/m2Single doses of 0.04 to 12 mg (6 per dose cohort, 12 on placebo), followed to day 29Terminal half-life 310 to 366 h across 0.4 to 12 mg; body weight change at 4 mg and 12 mg of -2.5% and -4.4% on day 29 against stable weight on placebo, with no significant difference from placebo at 0.04 to 1.2 mg; 9 participants on eloralintide had 16 adverse events, 15 of them mild1
Bhattachar and colleagues, Diabetes, Obesity and Metabolism, 2026 (Phase 1b, multiple dose)2Randomised, placebo-controlled, participant- and investigator-blinded, 12 weeks, no dose escalation; all nine authors Lilly employees and stockholders100 adults with obesity or overweight, mean age 44, 29% female, mean BMI 32.6 kg/m2; people with diabetes excluded1.2, 3, 6 or 12 mg once weekly for 12 weeks (placebo n=27)Placebo-adjusted weight reduction at week 12 of 2.6% (1.2 mg), 8.9% (3 mg), 8.5% (6 mg), 11.3% (12 mg), while the placebo group showed a 0.2% increase; the difference from placebo was significant for the 3, 6 and 12 mg groups at week 12; 13 participants left the study for adverse events; 4 had mood-related events2
Billings and colleagues, Lancet, 2025 (Phase 2, NCT06230523)3Multicentre, double-blind, randomised (2:1:1:1:2:1:2), placebo-controlled; sponsor Eli Lilly; seven of the ten authors are Lilly employees and stockholders263 adults at 46 US centres, BMI 30 or higher, or 27 or higher with a weight-related comorbidity, without type 2 diabetes1, 3, 6 or 9 mg weekly, or escalation to 9 mg from 6 mg or 3 mg, for 48 weeks (placebo n=53)Efficacy-estimand weight change of -9% (1 mg) to -20% (9 mg and 6-9 mg) against -0.4% on placebo; nausea 11% to 64% across regimens against 14% on placebo, and fatigue 0% to 46% against 12% on placebo3

No controlled trial of eloralintide by an investigator without a Lilly tie was identified in PubMed or ClinicalTrials.gov, and no Phase 3 result was identified. The open-label Phase 1 study NCT06916065, which gave eloralintide alone and with tirzepatide to 188 participants with overweight or obesity, is listed as completed on 19 January 2026; its entry carries no posted results.5 The Phase 3 study ENLIGHTEN-2 (NCT07282600) began on 15 December 2025 and is double-blind and placebo-controlled in adults with obesity or overweight and type 2 diabetes, with 1035 participants estimated.4 The same registry search listed further Lilly-sponsored Phase 3 entries, including NCT07321886 (obesity or overweight without type 2 diabetes), NCT07369011 (obstructive sleep apnea) and NCT07353931 (knee osteoarthritis pain), all recruiting.

Deeper analysis: the Phase 2 trial (Billings, Lancet, 2025)

Billings and colleagues report a 48-week Phase 2 trial; the first author is at Endeavor Health and the University of Chicago, and seven of the ten authors are Eli Lilly employees.3 The aim was "evaluating the efficacy and safety of a range of doses and dose escalation schemes of once-per-week eloralintide versus placebo in adults with obesity or overweight and had at least one weight-related comorbidity".3 Participants had a mean age of 49.0 years, a mean bodyweight of 109.1 kg and a mean BMI of 39.1 kg/m2; 204 (78%) were female and 205 (78%) White.3 Group sizes were 1 mg n=28, 3 mg n=24, 6 mg n=28, 9 mg n=54, 6-9 mg n=24 and 3-9 mg n=52, against placebo n=53.3 The primary endpoint was "percent change in bodyweight from baseline after 48 weeks of treatment", and efficacy analyses "included all randomly assigned participants".3 The reported change on the efficacy estimand was -20% on 9 mg (95% CI -22·7 to -17·5) and -18% on 6 mg (-20·7 to -14·5), against -0·4% on placebo (-2·2 to 1·4).3 The authors conclude that eloralintide "produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated".3 Adverse events were reported by regimen: nausea 11% (1 mg), 13% (3 mg), 64% (6 mg), 33% (9 mg), 54% (6-9 mg), 25% (3-9 mg) and 14% (placebo); the rate is not steadily higher with dose across these groups.3 The registry entry for the trial, which Lilly sponsors, lists the safety time frame as up to 58 weeks and shows 0 deaths in each of the seven groups.6 It lists serious adverse events in 3 of 53 on placebo, 3 of 28 on 1 mg, 1 of 24 on 3 mg, 1 of 28 on 6 mg, 3 of 54 on 9 mg, 2 of 24 on 6-9 mg and 1 of 52 on 3-9 mg.6 Participant flow in the registry shows that 15 of 28 on 1 mg and 38 of 53 on placebo completed the study, against 48 of 54 on 9 mg; 2 on placebo, 2 on 1 mg, 1 on 6 mg, 1 on 9 mg and 2 on 3-9 mg withdrew for an adverse event.6 The registry's posted per-group weight values were not used here, because their group labels do not line up with the group counts listed beside them.6 The authors' own limitations could not be reported: only the journal record's summary was retrieved, and the full text is not in PubMed Central.3 Eli Lilly funded the trial; Hsia and Bays list research support from Lilly, and Billings lists consulting fees from and advisory panel service for Lilly.3

Deeper analysis: the Phase 1 multiple-dose trial (Bhattachar, 2026)

Bhattachar and colleagues (Diabetes, Obesity and Metabolism, 2026) ran a 12-week, Phase 1b, randomised, placebo-controlled multiple ascending dose trial at three US centres.2 Participants were adults aged 18 to 65 with a BMI of 27 to 40 kg/m2 (30 to 45 in cohort five), excluding type 1 or 2 diabetes.2 Dosing was "without dose escalation", at 1.2, 3, 6 and 12 mg once weekly.2 The primary objective was safety and tolerability, with body weight and gastric emptying as secondary pharmacodynamic endpoints.2 Of 100 participants, 78 (78.0%) completed the study; 22 discontinued, 13 of them for adverse events.2 The placebo-adjusted weight reduction at week 12 was 11.3% on 12 mg, and the mean change differed from placebo for the 3, 6 and 12 mg groups at week 12 and the 6 and 12 mg groups at week 21.2 Overall, 59 participants (59.0%) reported 142 adverse events, most of them mild; no deaths occurred, and the two serious adverse events (a motor vehicle accident on placebo and acute kidney injury at 6 mg) were judged by the investigator not related to treatment.2 Four participants had mood-related events: depressed mood in three (one at 6 mg, two at 12 mg, all mild) and one persistent depressive disorder at 12 mg, "moderate in severity and lasting 4 days".2 All three participants at 12 mg with mood-related events were discontinued from treatment, and the events resolved in 2 to 4 days; fatigue accompanied 2 of the 4 events.2 The authors write that "Further exposures will allow additional understanding of the overall safety profile and tolerability".2 Gastrointestinal events were infrequent: nausea in 8% and vomiting in 4% of those on eloralintide, and "no discontinuations were due to nausea, vomiting, or diarrhoea".2 At the higher doses, acetaminophen exposure fell modestly after the first dose and returned to baseline on repeated dosing, with a dose-related increase on Day 80 compared with placebo; the authors read this as suggesting "that any effect on gastric emptying may be transient" and say "These results require confirmation".2 The authors name "the small sample size" as a key limitation, say the 12-week duration is insufficient to fully evaluate long-term weight loss, and call the appetite scores "hypothesis generating".2 Sample size was not powered: "no power calculations were performed", and no multiplicity adjustments were made.2 Eli Lilly funded the study (grant listed as Eli Lilly and Company), and all nine authors are Lilly employees and stockholders.2 The funding statement adds that the sponsor "was involved in the study design, data collection, data analyses, data interpretation, and report writing".2

Deeper analysis: the Phase 1 single-dose trial (Briere, 2025)

Briere and colleagues (Molecular Metabolism, 2025) combined laboratory, rat and monkey work with a Phase 1 single ascending dose trial (NCT05295940); only the human trial is described here.1 Six participants per dose cohort received eloralintide (36 in total) and 12 received placebo.1 Weight fell significantly versus placebo only at the 4 mg and 12 mg doses, with no significant difference at 0.04 to 1.2 mg.1 Two participants had 4 gastrointestinal events, including one moderate vomiting event, and "No serious AEs were reported".1 The authors write that at 12 mg "the underlying event rate is poorly estimated with this small sample size".1 They also state that the weight evaluation "is limited by small sample size" and "by a study population that was not limited to individuals with overweight or obesity".1 Another stated limitation is that cagrilintide's "shorter Tmax and half-life" relative to eloralintide could explain differences in potency seen in the animal work.1 All authors are Eli Lilly employees and shareholders, and Lilly funded the study.1

5

Doses reported in studies and on labels

No label or approved dose for eloralintide was identified; the figures below are doses given in the trials, and the app's typical range of 1 to 9 mg per week matches the fixed doses of the Phase 2 trial.

Table 5.1Doses reported in studies and on labels4 rows
StudyDoses and scheduleComparator, route, duration and nReference
Briere, Phase 1 single dose0.04, 0.12, 0.4, 1.2, 4 and 12 mg, oncePlacebo; subcutaneous injection; followed to day 29; 6 per dose cohort, 12 on placebo, healthy participants1
Bhattachar, Phase 1b multiple dose1.2, 3, 6 or 12 mg once weekly, no dose escalationPlacebo; subcutaneous; 12 weeks; n=8, 6, 23 and 36 on 1.2, 3, 6 and 12 mg; placebo n=272
Billings, Phase 2, fixed doses1, 3, 6 or 9 mg once weeklyPlacebo; subcutaneous; 48 weeks; n=28, 24, 28 and 54; placebo n=533
Billings, Phase 2, escalation regimens6 mg for 20 weeks then 9 mg for 28 weeks (6-9 mg, n=24); 3 mg for 4 weeks, 6 mg for 4 weeks, then 9 mg for 40 weeks (3-9 mg, n=52)Placebo; subcutaneous, once weekly; 48 weeks in total; the registry labels the second regimen 3/6/9 mg6

The Phase 3 registry entry lists four eloralintide arms (Dose 1 to Dose 4) without stating the doses in the entry text read.4

In the Phase 2 trial, nausea and fatigue were the most common adverse events, with fatigue at 43% on 9 mg and 46% on 6-9 mg against 12% on placebo.3 The registry entry for the same trial lists serious adverse events in 3 of 53 on placebo, 3 of 28 on 1 mg, 1 of 24 on 3 mg, 1 of 28 on 6 mg, 3 of 54 on 9 mg, 2 of 24 on 6-9 mg and 1 of 52 on 3-9 mg, with 0 deaths in each group.6 In the Phase 1 multiple-dose trial, adverse events in at least 10% of those on eloralintide were decreased appetite (19.2%), headache (12.3%), COVID-19 (11.0%) and fatigue (11.0%).2 Injection site reactions were reported in 33.3% at 3 mg, 21.7% at 6 mg and 13.9% at 12 mg against 3.7% on placebo, most of them mild.2 Mood-related events at 12 mg (three participants, all discontinued from treatment) are described in the Phase 1 analysis above.2 In the single-dose trial, 9 participants on eloralintide reported 16 adverse events, 15 of them mild.1 These are short trials of small groups, apart from the 48-week Phase 2 trial; the Phase 1 authors state that the "safety of eloralintide is unknown" over the long term.2

The app lists HbA1c, fasting glucose, heart rate and body weight as markers to monitor. Body weight was the primary endpoint of the Phase 2 trial, which excluded people with type 2 diabetes.3 In the Phase 1 multiple-dose trial, mean fasting plasma glucose "generally did not change from baseline to Day 80" in a normoglycaemic group, and no treatment-related changes were seen in glucose, insulin or C-peptide areas under the curve, although nominal increases in the insulin and C-peptide incremental areas under the curve were observed at higher doses, with high within-group variability.2 The authors write that "Further evaluation in dysglycemic individuals will be needed to more definitively evaluate the effects of eloralintide on glucose control".2 No HbA1c result for eloralintide was identified in the records read. Mean pulse rate fell from the first week: at week 12 the change was -14.4 bpm on 12 mg against -3.4 bpm on placebo, with no reports of symptomatic bradycardia.2 The Phase 2 registry entry excluded people with "bradyarrhythmia and/or sinus bradycardia at screening and baseline".6 Blood pressure showed mean decreases in both eloralintide and placebo arms "with no clear dose relationship".2 Clinical laboratory results showed "No clinically meaningful trends", and calcium and bone turnover markers showed no trends with dose or duration.2

8

Regulatory and anti-doping status

No approval by a regulator was identified: DailyMed returned no eloralintide label, and the Phase 3 program is recruiting.4 The 2026 WADA Prohibited List places under S0 "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development".7 The list text does not name eloralintide, and the sources read contain no WADA statement about it specifically.7

9

What is not known

No Phase 3 efficacy or safety result was identified in PubMed or ClinicalTrials.gov. Long-term safety is stated as unknown by the Phase 1 authors: "safety of eloralintide is unknown".2 The cause of the mood-related events at 12 mg is not established; the authors say only that further exposures "will allow additional understanding".2 The biological relevance of the receptor selectivity is open: "there is no established minimum selectivity threshold to define biologically relevant selectivity".1 Effects on blood glucose in people with diabetes are not reported in the records read; the Phase 1 authors write that evaluation "in dysglycemic individuals will be needed".2 The Phase 1 multiple-dose authors say the gastric-emptying finding "require[s] confirmation", so effects on the absorption of other medicines are not established.2 A bioavailability figure for the subcutaneous route has not been published in the records read, and the app's 80% is modelled.

What is the half-life of eloralintide?

A Phase 1 single-dose trial reported a terminal geometric mean half-life of 310 to 366 hours (12.9 to 15.3 days), and the app lists 336 hours (14 days).1 The multiple-dose Phase 1 paper describes a "~14‐day half‐life".2

How long does eloralintide take to reach its peak level?

The median time to maximum concentration was 72.0 to 132.2 hours across single doses of 0.04 to 12 mg, and the app lists about 24 hours.1

Is eloralintide approved?

No approval was identified: a DailyMed search returned no label for eloralintide, and Lilly's Phase 3 study ENLIGHTEN-2 is recruiting.4

Is eloralintide banned by WADA?

The 2026 WADA list does not name eloralintide, but its S0 class prohibits at all times any pharmacological substance not addressed by any of the subsequent sections of the List and with no current approval for human therapeutic use, with "drugs under pre-clinical or clinical development" given as an example.7

Is eloralintide the same as cagrilintide?

No: Lilly's authors describe eloralintide as selective for amylin receptors over calcitonin receptors, and cagrilintide as a non-selective agonist that activates amylin and calcitonin receptors with comparable potency.1

How much weight did people lose in the eloralintide Phase 2 trial?

Mean weight change at 48 weeks on the efficacy estimand was -9% on 1 mg to -20% on 9 mg and 6-9 mg, against -0.4% on placebo, in 263 adults without type 2 diabetes.3 Lilly funded the trial and seven of its ten authors are Lilly employees.3

What side effects were reported with eloralintide?

Nausea and fatigue were the most common adverse events in the Phase 2 trial, with fatigue at 43% on 9 mg against 12% on placebo.3 In the 12-week Phase 1 trial, four participants had mood-related events (one at 6 mg and three at 12 mg), and all three at 12 mg were discontinued from treatment.2

What is the bioavailability of eloralintide?

No published bioavailability figure was identified, and the app's 80% is a modelled value.5

Who makes eloralintide?

Eli Lilly and Company sponsors the registered eloralintide trials, including the Phase 3 study ENLIGHTEN-2.4

12

References

  1. Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab 2025. PMID 41109426
  2. Bhattachar S, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab 2026. PMID 41559929
  3. Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2025. PMID 41207310
  4. Eli Lilly and Company. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2). ClinicalTrials.gov NCT07282600, status verified November 2026. NCT07282600
  5. Eli Lilly and Company. A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity. ClinicalTrials.gov NCT06916065, status verified January 2026. NCT06916065
  6. Eli Lilly and Company. A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight. ClinicalTrials.gov NCT06230523, results posted June 2026. NCT06230523
  7. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list